Targeting RSK2 in human malignancies

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.1, 2011-01, pp. : 11-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paving the way for targeting RSK in cancer

By Romeo Yves Roux Philippe P

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 5-9

Informa Healthcare

Access to resources Recommend Favorite

Targeting mTOR Pathways in Human Malignancies

Current Pharmaceutical Design, Vol. 18, Iss. 19, 2012-06 ,pp. : 2766-2777

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise

Current Pharmaceutical Design, Vol. 14, Iss. 21, 2008-07 ,pp. : 2051-2060

Bentham Science Publishers

Access to resources Recommend Favorite

The promise and challenges of targeting RSK for the treatment of cancer

By Stratford Anna L Dunn Sandra E

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 1-4

Informa Healthcare

Access to resources Recommend Favorite

Targeting the BCL-2 family in malignancies of germinal centre origin

By Spender Lindsay C Inman Gareth J

Expert Opinion on Therapeutic Targets, Vol. 13, Iss. 12, 2009-12 ,pp. : 1459-1472

Informa Healthcare

Access to resources Recommend Favorite